Cargando…
Impfstoffe gegen COVID-19
The ongoing COVID-19 pandemic represents an emergency situation of devastating proportions. To mitigate its effects, several safe and effective vaccines have been developed in a very short period of time. Currently, four vaccines have been approved by the European Medicines Agency (EMA) and are in u...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493542/ https://www.ncbi.nlm.nih.gov/pubmed/34613428 http://dx.doi.org/10.1007/s00108-021-01164-0 |
_version_ | 1784579132639674368 |
---|---|
author | Fathi, Anahita Mellinghoff, Sibylle C. |
author_facet | Fathi, Anahita Mellinghoff, Sibylle C. |
author_sort | Fathi, Anahita |
collection | PubMed |
description | The ongoing COVID-19 pandemic represents an emergency situation of devastating proportions. To mitigate its effects, several safe and effective vaccines have been developed in a very short period of time. Currently, four vaccines have been approved by the European Medicines Agency (EMA) and are in use in Germany. These include two mRNA vaccines and two vector-based vaccines. They all show very good protective efficacy, especially against severe courses of disease and can significantly contain the pandemic by reducing viral transmission. This article focuses on the development and mechanism of action of the vaccines, their safety and efficacy profile as well as indications for vaccination and current recommendations for the use of vaccines in special groups of people, such as convalescent, immunosuppressed and pregnant patients. Finally, currently open scientific questions are addressed. |
format | Online Article Text |
id | pubmed-8493542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-84935422021-10-06 Impfstoffe gegen COVID-19 Fathi, Anahita Mellinghoff, Sibylle C. Internist (Berl) CME The ongoing COVID-19 pandemic represents an emergency situation of devastating proportions. To mitigate its effects, several safe and effective vaccines have been developed in a very short period of time. Currently, four vaccines have been approved by the European Medicines Agency (EMA) and are in use in Germany. These include two mRNA vaccines and two vector-based vaccines. They all show very good protective efficacy, especially against severe courses of disease and can significantly contain the pandemic by reducing viral transmission. This article focuses on the development and mechanism of action of the vaccines, their safety and efficacy profile as well as indications for vaccination and current recommendations for the use of vaccines in special groups of people, such as convalescent, immunosuppressed and pregnant patients. Finally, currently open scientific questions are addressed. Springer Medizin 2021-10-06 2021 /pmc/articles/PMC8493542/ /pubmed/34613428 http://dx.doi.org/10.1007/s00108-021-01164-0 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | CME Fathi, Anahita Mellinghoff, Sibylle C. Impfstoffe gegen COVID-19 |
title | Impfstoffe gegen COVID-19 |
title_full | Impfstoffe gegen COVID-19 |
title_fullStr | Impfstoffe gegen COVID-19 |
title_full_unstemmed | Impfstoffe gegen COVID-19 |
title_short | Impfstoffe gegen COVID-19 |
title_sort | impfstoffe gegen covid-19 |
topic | CME |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493542/ https://www.ncbi.nlm.nih.gov/pubmed/34613428 http://dx.doi.org/10.1007/s00108-021-01164-0 |
work_keys_str_mv | AT fathianahita impfstoffegegencovid19 AT mellinghoffsibyllec impfstoffegegencovid19 |